Evidence map›Paper›PMID 24211331›Full record

ArticleAntiviral research2014

Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.

Jeffrey D Meteer, Raymond F Schinazi, John W Mellors, Nicolas Sluis-Cremer

Abstract read
In one paragraph

Article in Antiviral research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jeffrey D MeteerDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: jdm69@pitt.edu.
Raymond F SchinaziCenter for AIDS Research, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Veterans Affairs Medical Center, Decatur, GA, USA. Electronic address: rschina@emory.edu.
John W MellorsDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: jwm1@pitt.edu.
Nicolas Sluis-CremerDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: nps2@pitt.edu.
University of Pittsburgh · USEmory University · US

Funding

Novel mechanisms of HIV resistance to RTIsR01AI081571 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SLUIS-CREMER, NICOLAS PAUL · 2009 to 2018
$3.0M
Rational Design of NRTI for Drug Resistant HIV-1R01AI071846 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MELLORS, JOHN W · 2007 to 2010
$2.9M
NIAID NIH HHS AI071846NIAID NIH HHS AI081571NIAID NIH HHS R01 AI071846NIAID NIH HHS R01 AI081571
6 · The paper itself

Abstract

We reported that 3'-azido-2',3'-dideoxyguanosine (3'-azido-ddG) selected for the L74V, F77L, and L214F mutations in the polymerase domain and K476N and V518I mutations in the RNase H domain of HIV-1 reverse transcriptase (RT). In this study, we have defined the molecular mechanisms of 3'-azido-ddG resistance by performing in-depth biochemical analyses of HIV-1 RT containing mutations L74V, F77L, V106I, L214F, R277K, and K476N (SGS3). The SGS3 HIV-1 RT was from a single-genome-derived full-length RT sequence obtained from 3'-azido-ddG resistant HIV-1 selected in vitro. We also analyzed two additional constructs that either lacked the L74V mutation (SGS3-L74V) or the K476N mutation (SGS3-K476N). Pre-steady-state kinetic experiments revealed that the L74V mutation allows RT to effectively discriminate between the natural nucleotide (dGTP) and 3'-azido-ddG-triphosphate (3'-azido-ddGTP). 3'-azido-ddGTP discrimination was primarily driven by a decrease in 3'-azido-ddGTP binding affinity (Kd) and not by a decreased rate of incorporation (kpol). The L74V mutation was found to severely impair RT's ability to excise the chain-terminating 3'-azido-ddG-monophosphate (3'-azido-ddGMP) moiety. However, the K476N mutation partially restored the enzyme's ability to excise 3'-azido-ddGMP on an RNA/DNA, but not on a DNA/DNA, template/primer by selectively decreasing the frequency of secondary RNase H cleavage events. Collectively, these data provide strong additional evidence that the nucleoside base structure is major determinant of HIV-1 resistance to the 3'-azido-2',3'-dideoxynucleosides.

Indexed as

Drug Resistance, ViralAnti-HIV AgentsDideoxynucleosidesHIV-1HIV Reverse TranscriptaseHumansKineticsMutant ProteinsMutation, Missensepol Gene Products, Human Immunodeficiency VirusSelection, Genetic3'-azido-2',3'-dideoxyguanosineAnti-HIV AgentsDideoxynucleosidesHIV Reverse TranscriptaseMutant Proteinspol Gene Products, Human Immunodeficiency Virusreverse transcriptase, Human immunodeficiency virus 13′-azido-2′,3′-dideoxyguanosine3′-Azido-2′,3′-dideoxyguanosine3′-Azido-ddG3′-azido-ddG-monophosphate3′-Azido-ddGMP3′-Azido-ddGTP3′-azido-ddG-triphosphate50% inhibitory concentrationAZTdiphosphateDiscriminationDPExcisionHIV-1IC(50)monophosphateMPNRTINRTIsnucleoside reverse transcriptase inhibitorsnucleoside RT inhibitorResistancereverse transcriptaseReverse transcriptaseribonuclease HRNase HRTtemplate/primerT/PTPtriphosphatewild-typeWTzidovudine

Identifiers

PMID24211331
PMCPMC3889670
OpenAlexW2088628221

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.